French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...

Elsa Mendoza navigates life with multiple sclerosis, using a wheelchair while her son, Fernando, excels as a quarterback ...